Literature DB >> 33349459

Anti-capsular immunity to Streptococcus pneumoniae serotype 22F prevents bacterial transmission in murine colonization and influenza virus co-infection models.

Taylor Schmit1, Mikale Kuntz1, Devarshi Patel1, M Nadeem Khan2.   

Abstract

We evaluated the effectiveness of anti-22F serotype immunity in the prevention of Streptococcus pneumoniae (Spn) bacterial transmission during colonization and influenza virus co-infection. Mice were immunized with 22F formulation and later colonized with Spn or co-infected with Spn and influenza virus. The 22F antisera exhibited strong reactivity to 22F bacteria and promoted the opsonic uptake of Spn by the neutrophils. The 22F vaccination led to a significant reduction of bacterial densities in the nasopharynx and prevented bacterial transmission during colonization and co-infection. The transfer of 22F antisera to infant mice resulted in reduced bacterial transmission in colonization and co-infection models. Published by Elsevier Ltd.

Entities:  

Keywords:  Co-infection; Inflammation; Influenza; Spn; Spn transmission; Upper respiratory infection

Mesh:

Year:  2020        PMID: 33349459      PMCID: PMC7877192          DOI: 10.1016/j.vaccine.2020.11.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Herd immunity after pneumococcal conjugate vaccination.

Authors:  Werner C Albrich; Shabir A Madhi; Kathryn E Lafond; Keith P Klugman
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

3.  Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans.

Authors:  M Nadeem Khan; Michael E Pichichero
Journal:  Vaccine       Date:  2012-02-17       Impact factor: 3.641

4.  Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody.

Authors:  Ankur B Dalia; Jeffrey N Weiser
Journal:  Cell Host Microbe       Date:  2011-11-17       Impact factor: 21.023

5.  Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.

Authors:  Nick J Andrews; Pauline A Waight; Polly Burbidge; Emma Pearce; Lucy Roalfe; Marta Zancolli; Mary Slack; Shamez N Ladhani; Elizabeth Miller; David Goldblatt
Journal:  Lancet Infect Dis       Date:  2014-07-17       Impact factor: 25.071

Review 6.  The role of influenza in the severity and transmission of respiratory bacterial disease.

Authors:  Michael J Mina; Keith P Klugman
Journal:  Lancet Respir Med       Date:  2014-08-15       Impact factor: 30.700

Review 7.  The fundamental link between pneumococcal carriage and disease.

Authors:  Birgit Simell; Kari Auranen; Helena Käyhty; David Goldblatt; Ron Dagan; Katherine L O'Brien
Journal:  Expert Rev Vaccines       Date:  2012-07       Impact factor: 5.217

8.  Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination.

Authors:  G L Masala; M Lipsitch; C Bottomley; S Flasche
Journal:  J R Soc Interface       Date:  2017-11       Impact factor: 4.118

9.  Surveillance of the impact of pneumococcal conjugate vaccines in developing countries.

Authors:  Gail L Rodgers; Keith P Klugman
Journal:  Hum Vaccin Immunother       Date:  2015-08-26       Impact factor: 3.452

10.  Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain.

Authors:  Julio Sempere; Sara de Miguel; Fernando González-Camacho; José Yuste; Mirian Domenech
Journal:  Front Microbiol       Date:  2020-02-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.